Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Gene Therapy for Transfusion Dependent Beta-thalassemia (TIGET-BTHAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02453477
Recruitment Status : Active, not recruiting
First Posted : May 25, 2015
Last Update Posted : June 28, 2019
Sponsor:
Collaborators:
Fondazione Telethon
Orchard Therapeutics
Information provided by (Responsible Party):
Alessandro Aiuti, IRCCS San Raffaele

Brief Summary:
This is a phase I/II study evaluating safety and efficacy of autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene for the treatment of patients affected by transfusion dependent beta-thalassemia

Condition or disease Intervention/treatment Phase
Beta-Thalassemia Genetic: Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene Phase 1 Phase 2

Detailed Description:

Both adults and pediatric patients will be treated with genetically modified autologous hematopoietic stem cells collected from mobilized peripheral blood (or bone marrow for patients < 8 years in case mobilization will not be feasible) and transduced with GLOBE lentiviral vector encoding for the human beta-globin gene.

This study will enroll 10 patients allocated in 3 groups, according to age and conditioning regimen:

  1. 3 adults (≥18 years) conditioned with treosulfan and thiotepa
  2. 3 elderly children (8-17 years) conditioned with treosulfan and thiotepa
  3. 4 younger children (3-7 years) conditioned with treosulfan and thiotepa Enrolment will start in adult patients. Pediatric patients will be included once evidence of preliminary safety and biological efficacy is shown in at least 2 adults.

Patients are included regardless of the beta globin gene mutation, provided an adequate cardiac, renal, hepatic and pulmonary function is demonstrated. Patients with severe iron overload are excluded as well as patients with active viral infections. Pediatric patients can be enrolled only in absence of a human leukocyte antigen (HLA)-identical sibling or a suitable 10/10 matched unrelated donor.

The treated patients will be followed for 2 years. After completion of the 2 years follow up, patients will be enrolled in a long term follow up study and followed up for at least other additional 6 years.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study Evaluating Safety and Efficacy of Autologous Hematopoietic Stem Cells Genetically Modified With GLOBE Lentiviral Vector Encoding for the Human Beta-globin Gene for the Treatment of Patients Affected by Transfusion Dependent Beta-thalassemia
Study Start Date : May 2015
Estimated Primary Completion Date : August 2019
Estimated Study Completion Date : August 2019


Arm Intervention/treatment
Experimental: Adults

≥18 years (3 subjects) The ATIMP consists of autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the beta-globin gene re-suspended in their final formulation medium.

Dosage indications The target dose in the transduced product is 5x10(6) cells/Kg CD34+cells, with a minimum dose of 2x10(6)/Kg and a maximum dose of 20x10(6)/Kg, depending on the yield of cells.

The product will be injected intraosseously.

Genetic: Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene
Autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the human beta-globin gene resuspended in their final formulation medium. The target dose in the transduced product is 5x10^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10^6/Kg and a maximum dose of 20 x 10^6/Kg, depending on the yield of cells. The product will be injected intraosseously.

Experimental: Elderly children

8-17 years (3 subjects) The ATIMP consists of autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the beta-globin gene re-suspended in their final formulation medium.

Dosage indications The target dose in the transduced product is 5x10(6) cells/Kg CD34+cells, with a minimum dose of 2x10(6)/Kg and a maximum dose of 20x10(6)/Kg, depending on the yield of cells.

The product will be injected intraosseously.

Genetic: Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene
Autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the human beta-globin gene resuspended in their final formulation medium. The target dose in the transduced product is 5x10^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10^6/Kg and a maximum dose of 20 x 10^6/Kg, depending on the yield of cells. The product will be injected intraosseously.

Experimental: Younger children

3-7 years (4 subjects) The ATIMP consists of autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the beta-globin gene re-suspended in their final formulation medium.

Dosage indications The target dose in the transduced product is 5x10(6) cells/Kg CD34+cells, with a minimum dose of 2x10(6)/Kg and a maximum dose of 20x10(6)/Kg, depending on the yield of cells.

The product will be injected intraosseously.

Genetic: Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene
Autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the human beta-globin gene resuspended in their final formulation medium. The target dose in the transduced product is 5x10^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10^6/Kg and a maximum dose of 20 x 10^6/Kg, depending on the yield of cells. The product will be injected intraosseously.




Primary Outcome Measures :
  1. Overall survival [ Time Frame: 2 years ]
    Number of patients alive all over the trial

  2. Achievement of hematological engraftment [ Time Frame: within day +60 after gene therapy ]
    Haematological engraftment is defined as first day of neutrophil count >500/mm3 and platelets >20,000/mm3 on 3 consecutive blood counts.

  3. Safety of the administration of autologous haematopoietic stem cells transduced with LV-GLOBE [ Time Frame: 0-24 months after gene therapy ]
    • short-term tolerability: the percentage of patients not experiencing short-term (0-24 hours from injection) adverse events (of any grade) and systemic reactions.
    • absence of Replication Competent Lentivirus (RCL): the percentage of subjects without RCL in the 24 months from injection.
    • absence of abnormal clonal proliferation: the percentage of subjects without abnormal clonal proliferation in the 24 months from injection.

  4. Short-term safety and tolerability of the different conditioning regimens [ Time Frame: from day -5 (first day of conditioning treatment) to day 100 after gene therapy ]
    The percentage of patients with the following clinical events from day -5 to +100 days from injection: NCI (National Cancer Institute Common Terminology Criteria grading) ≥2 and metabolic/laboratory NCI ≥3.

  5. Overall safety and tolerability measured by AE recording [ Time Frame: 0-24 months after gene therapy ]
    The number of AEs (adverse events) and SAEs (serious adverse events) and the percentage of subjects experiencing AEs and SAEs in the 24 months post injection will be summarized by severity and within body system involved.

  6. Polyclonal engraftment [ Time Frame: From 6 months to 2 years after gene therapy ]
    The percentage of subjects with polyclonality of haematopoiesis will be estimated at 6, 12, 18 and 24 months from injection. Polyclonality of haematopoiesis will be defined as > 1000 unique integration sites retrieved from peripheral blood and/or bone marrow cells.

  7. Reduction in transfusion frequency up to transfusion independence [ Time Frame: from -7 months before gene therapy to 2 years after gene therapy ]
    Transfusions will be recorded as mLs of blood/kg/months


Secondary Outcome Measures :
  1. Transfusion independence [ Time Frame: 9 months, 1, 1.5 and 2 years after gene therapy ]
    Transfusion independence is defined as ≤ 1 transfusion in the previous 6 months

  2. Adequate haemoglobin level [ Time Frame: 0-24 months after gene therapy ]
    Haemoglobin level will be assessed by full blood counts in patients achieving transfusion independence. Adequate haemoglobin is defined as haemoglobin >9 g/dl in adults and >10 g/dl in children.

  3. Adequate engraftment of genetically corrected cells [ Time Frame: 6, 12, and 24 months after gene therapy ]
    Engraftment will be assessed by vector-specific quantitative Polymerase Chain reaction (PCR) on bone marrow. Adequate engraftment is defined as ≥ 0.15 VCN/genome. (VCN = Vector Copy Number)

  4. Transgene expression [ Time Frame: 6, 12, and 24 months after gene therapy ]
    Transgene expression will be evaluated by globin chains and/or hemoglobin synthesis on peripheral blood and/or bone marrow samples by HPLC and/or electrophoresis analysis

  5. Improvement of health-related quality of life [ Time Frame: 12 and 24 months ]
    Health-related quality of life will be assessed by the use of standardized questionnaires



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   3 Years to 64 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent
  • Transfusion-dependent beta-thalassemia (any genotype). Transfusion dependence is defined as receiving ≥ 8 transfusions of blood per year over a minimum of 2 years.
  • Karnofsky Index or Lansky > 80%
  • Age ≥ 3 years and < 65 years
  • Adequate cardiac, renal, hepatic and pulmonary functions as evidenced by:

    • Left ventricular ejection fraction (LVEF) greater than 45% by echo and normal ECG or presence of abnormalities not significant for cardiac disease. Absence of severe pulmonary hypertension
    • Diffusing capacity of the lung for carbon monoxide (DLCO) > 50% and forced expiratory volume in 1 sec (FEV1) and forced expiratory vital capacity (FVC) > 60% predicted (if non cooperative: pulse oximetry > 95 % in room air)
    • Serum creatinine < 1.5 upper limit of normal
    • Absent-mild-moderate liver iron overload on T2*MRI (less than 12 months before enrolment)
    • Absent-mild-moderate cardiac iron overload T2*MRI (less than 12 months before enrolment)
    • Absence of severe liver fibrosis or cirrhosis on fibroscan or liver biopsy (less than 12 months before enrolment)
  • Low risk thrombophilic screen and negative history of significant previous thrombotic events
  • For all patients in reproductive age, agreement to use highly effective and adequate method of contraception while receiving treatment phase and for at least 12 months following drugs administration (including both females of child bearing potential and males with partners of child bearing potential)
  • Good adherence to transfusion and chelation programme as indirect evidence of good adherence to treatment and follow-up evaluations for current trial
  • Availability of an adequate and well documented transfusion history (at least previous 6 months) or availability to follow a regular transfusion regimen according to guidelines and provide a detailed transfusion record of the 6 months prior to intervention phase

Exclusion Criteria:

  • Use of other investigational agents within 4 weeks prior to study enrolment (within 6 weeks if use of long-acting agents)
  • Severe, active viral, bacterial, or fungal infection at eligibility evaluation
  • Malignant neoplasia (except local skin cancer or cervical intraepithelial neoplasia) or exceptional family history of familial cancer syndromes
  • Myelodysplasia, cytogenetic alterations associated with neoplasia, or other serious haematological disorder than thalassemia
  • History of uncontrolled seizures
  • Other clinical conditions judged non compatible with the procedure and/or the treatment
  • Positivity for HIV (serology or RNA), and/or HbsAg and/or HBV DNA and/or HCV RNA (or negative HCV RNA but on antiviral treatment) and/or Treponema Pallidum or Mycoplasma active infection
  • Active alcohol or substance abuse within 6 months of the study
  • Pregnancy or lactation
  • Previous allogeneic bone marrow transplantation or gene therapy
  • For paediatric patients only: availability of an HLA-matched donor (sibling or of a suitable 10/10 matched unrelated donor).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02453477


Locations
Layout table for location information
Italy
Ospedale San Raffaele
Milano, Italy, 20132
Sponsors and Collaborators
IRCCS San Raffaele
Fondazione Telethon
Orchard Therapeutics
Investigators
Layout table for investigator information
Principal Investigator: Alessandro Aiuti, MD, PhD Ospedale San Raffaele
Study Chair: Fabio Ciceri, MD Ospedale San Raffaele
Study Chair: Sarah Marktel, MD Ospedale San Raffaele
Study Chair: Maria Domenica Cappellini, MD IRCCS Policlinico Foundation
Study Director: Giuliana Ferrari, PhD Telethon Institute of Gene Therapy, Ospedale San Raffaele

Publications:

Layout table for additonal information
Responsible Party: Alessandro Aiuti, Director of Pediatric Clinical Research Unit, IRCCS San Raffaele
ClinicalTrials.gov Identifier: NCT02453477     History of Changes
Other Study ID Numbers: 2014-004860-39 (EudraCT)
First Posted: May 25, 2015    Key Record Dates
Last Update Posted: June 28, 2019
Last Verified: June 2019
Keywords provided by Alessandro Aiuti, IRCCS San Raffaele:
Beta thalassemia
Gene therapy
Lentiviral vector
Additional relevant MeSH terms:
Layout table for MeSH terms
Thalassemia
beta-Thalassemia
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn